Acyclovir
Brand names: Sitavig, ZOVIRAX, Acyclovir, Acyclovir suspension, acyclovir, Zovirax, ACYCLOVIR, Avaclyr
Warnings
No boxed warning. Contraindicated in patients who "develop hypersensitivity to acyclovir or valacyclovir." Key warnings: "Renal failure, in some cases resulting in death, has been observed with acyclovir therapy," particularly with inadequate hydration or in patients with underlying renal impairment; and "Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy."
Contraindications
Acyclovir tablets are contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.
Overdose
Overdoses involving ingestion of up to 100 capsules (20 g) have been reported. Adverse events that have been reported in association with overdosage include agitation, coma, seizures, and lethargy. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Overdosage has been reported following bolus injections or inappropriately high doses and in patients whose fluid and electrolyte balance were not properly monitored. This has resulted in elevated BUN and serum creatinine and subsequent renal failure. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored (see DOSAGE AND ADMINISTRATION).
Drug interactions
Drug Interactions: See CLINICAL PHARMACOLOGY: Pharmacokinetics .
Uses
Acyclovir tablets are indicated for: - Acute treatment of herpes zoster (shingles) - Treatment of initial episodes and management of recurrent episodes of genital herpes - Treatment of chickenpox (varicella). The label notes effectiveness is greatest when therapy is started early after symptom onset.
Dosage forms & strengths
Acute Treatment of Herpes Zoster: 800 mg every 4 hours orally, 5 times daily for 7 to 10 days. Genital Herpes: Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for 10 days. Chronic Suppressive Therapy for Recurrent Disease: 400 mg 2 times daily for up to 12 months, followed by re-evaluation. Alternative regimens have included doses ranging from 200 mg 3 times daily to 200 mg 5 times daily. The frequency and severity of episodes of untreated genital herpes may change over time. After 1 year of therapy, the frequency and severity of the patient’s genital herpes infection should be re-evaluated to assess the need for continuation of therapy with acyclovir tablets. Intermittent Therapy: 200 mg every 4 hours, 5 times daily for 5 days. Therapy should be initiated at the earliest sign or symptom (prodrome) of recurrence. Treatment of Chickenpox: Children (2 years of age and older): 20 mg/kg per dose orally 4 times daily (80 mg/kg/day) for 5 days. Children over 40 kg should receive the adult dose for chickenpox. Adults and Children over 40 kg: 800 mg 4 times daily for 5 days. Intravenous acyclovir is indicated for the treatment of varicella-zoster infections in immunocompromised patients. When therapy is indicated, it should be initiated at the earliest sign or symptom of chickenpox. There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms. Patients With Acute or Chronic Renal Impairment: In patients with renal impairment, the dose of acyclovir tablets should be modified as shown in Table 3. Table 3. Dosage Modification for Renal Impairment Normal Dosage Regimen Creatinine Clearance (mL/min/1.73 m 2) Adjusted Dosage Regimen Dose (mg) Dosing Interval 200 mg every 4 hours > 10 0-10 200 200 every 4 hours, 5x daily every 12 hours 400 mg every 12 hours > 10 0-10 400 200 every 12 hours every 12 hours 800 mg every 4 hours > 25 10-25 0-10 800 800 800 every 4 hours, 5x daily every 8 hours every 12 hours Hemodialysis: For patients who require hemodialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a 6-hour dialysis period. Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis. Peritoneal Dialysis: No supplemental dose appears to be necessary after adjustment of the dosing interval.
All identified pills
N943 400
BLUE CAPSULE · Acyclovir
2 manufacturers
N943 400
BLUE OVAL · Acyclovir
19 manufacturers
N947 800
WHITE OVAL · Acyclovir
12 manufacturers
Prestium ZOVIRAX
BLUE CAPSULE · Acyclovir
2 manufacturers
QP146
BLUE OVAL · Acyclovir
QP146
BLUE OVAL · Acyclovir
4 manufacturers
QP146
BLUE OVAL · Acyclovir
2 manufacturers
R 607
GREEN OVAL · Acyclovir
RX504
WHITE CAPSULE · Acyclovir
3 manufacturers
RX504
WHITE CAPSULE · Acyclovir
2 manufacturers
RX504
WHITE OVAL · Acyclovir
2 manufacturers
RX505
WHITE CAPSULE · Acyclovir
2 manufacturers
RX505
WHITE OVAL · Acyclovir
RX652
WHITE CAPSULE · Acyclovir
3 manufacturers
S042
BLUE CAPSULE · Acyclovir
2 manufacturers
S047
WHITE ROUND · Acyclovir
2 manufacturers
Wellcome ZOVIRAX
BLUE CAPSULE · Acyclovir
2 manufacturers
Y212
WHITE ROUND · Acyclovir
10 manufacturers
Y213
WHITE CAPSULE · Acyclovir
6 manufacturers
ZOVIRAX 800
BLUE OVAL · Acyclovir
2 manufacturers
ZOVIRAX
WHITE HEXAGON (6 SIDED) · Acyclovir
2 manufacturers
Side effects
In controlled trials, the most frequent reactions were malaise (about 11.5%), nausea/vomiting (2.7%), and diarrhea (2.4%). Serious post-approval adverse events reported include CNS effects such as "aggressive behavior, agitation, ataxia, coma, confusion, decreased consciousness, delirium, dizziness," and renal/urogenital complications including "renal failure, renal pain," sometimes associated with crystalluria.